David W. Barbara
David W. Barbara has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
William J. Mauermann
From the Departments of Anesthesiology and Perioperative Medicine
7 shared publicationsBenjamin C. Smith
Mayo Clinic College of Medicine
4 shared publicationsJoseph A. Hyder
Department of Anesthesiology and Perioperative Medicine (Drs B. B. Smith, M. M. Smith, Hyder, Mauermann, Warner, Licatino, and Barbara), and Robert E. and Patricia E. Kern Center for the Science of Health Care Delivery (Dr Hyder), Mayo Clinic College of Medicine, Rochester, Minnesota
3 shared publications- Mark M. Smith
Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN
3 shared publications Stephen M. Broski
Mayo Clinic College of Medicine
3 shared publicationsCharles B. Rosen
Department of Surgery and William J. von Liebig Transplant Center, Mayo Clinic, Rochester, Minnesota
2 shared publications
Latest Publications
- 1 June 2019
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 128 (6) , 1168-1174
Intensive Care Unit Readmission After Left Ventricular Assist Device Implantation: Causes, Associated Factors, and Association With Patient Mortality
BACKGROUND: Previous studies on readmissions after left ventricular assist device (LVAD) implantation have focused on hospital readmissions after dismissal from the index hospitalization. Because few data exist, the purpose of this study was to examine intensive care unit (ICU) readmissions in patients during their initial hospitalization for LVAD implantation to determine reasons for, factors associated with, and incidence of mortality after ICU readmission. METHODS: A retrospective analysis was performed from February 2007 to March 2015 of patients at our institution receiving first-time LVAD implantation. After LVAD implantation, patients dismissed from the ICU who then required ICU readmission before hospital dismissal were compared to those not requiring ICU readmission before hospital dismissal with respect to preoperative, intraoperative, and postoperative factors. RESULTS: Among 287 LVAD patients, 266 survived their initial ICU admission, of which 49 (18.4%) required ICU readmission. The most common reasons for readmission were bleeding and respiratory failure. Factors found to be univariably associated with ICU readmission were preoperative hemoglobin, preoperative aspartate aminotransferase, preoperative atrial fibrillation, preoperative dialysis, longer cardiopulmonary bypass times, and higher intraoperative allogeneic blood transfusion requirements. Multivariable analysis revealed ICU readmission to be independently associated with preoperative dialysis (odds ratio, 12.86; 95% confidence interval, 3.16–52.28; P < .001). Overall mortality at 1 year was 22.6%. Survival after hospital dismissal was worse for patients who required ICU readmission during the index hospitalization (adjusted hazard ratio, 2.35; 95% confidence interval, 1.15–4.81; P = .019). CONCLUSIONS: ICU readmission after LVAD implantation occurred relatively frequently and was significantly associated with 1-year mortality after hospital dismissal. These data can perhaps be used to identify subsets of LVAD patients at risk for ICU readmission and may lead to implementation of practice changes to mitigate ICU readmissions. Future larger and prospective studies are warranted.
- 1 June 2019
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 128 (6) , 1168-1174
Intensive Care Unit Readmission After Left Ventricular Assist Device Implantation: Causes, Associated Factors, and Association With Patient Mortality
BACKGROUND: Previous studies on readmissions after left ventricular assist device (LVAD) implantation have focused on hospital readmissions after dismissal from the index hospitalization. Because few data exist, the purpose of this study was to examine intensive care unit (ICU) readmissions in patients during their initial hospitalization for LVAD implantation to determine reasons for, factors associated with, and incidence of mortality after ICU readmission. METHODS: A retrospective analysis was performed from February 2007 to March 2015 of patients at our institution receiving first-time LVAD implantation. After LVAD implantation, patients dismissed from the ICU who then required ICU readmission before hospital dismissal were compared to those not requiring ICU readmission before hospital dismissal with respect to preoperative, intraoperative, and postoperative factors. RESULTS: Among 287 LVAD patients, 266 survived their initial ICU admission, of which 49 (18.4%) required ICU readmission. The most common reasons for readmission were bleeding and respiratory failure. Factors found to be univariably associated with ICU readmission were preoperative hemoglobin, preoperative aspartate aminotransferase, preoperative atrial fibrillation, preoperative dialysis, longer cardiopulmonary bypass times, and higher intraoperative allogeneic blood transfusion requirements. Multivariable analysis revealed ICU readmission to be independently associated with preoperative dialysis (odds ratio, 12.86; 95% confidence interval, 3.16–52.28; P < .001). Overall mortality at 1 year was 22.6%. Survival after hospital dismissal was worse for patients who required ICU readmission during the index hospitalization (adjusted hazard ratio, 2.35; 95% confidence interval, 1.15–4.81; P = .019). CONCLUSIONS: ICU readmission after LVAD implantation occurred relatively frequently and was significantly associated with 1-year mortality after hospital dismissal. These data can perhaps be used to identify subsets of LVAD patients at risk for ICU readmission and may lead to implementation of practice changes to mitigate ICU readmissions. Future larger and prospective studies are warranted.
- 1 December 2018
- Published by Elsevier in Advances in Anesthesia
- Vol. 36 (1) , 99-123
Left Ventricular Assist Devices and Noncardiac Surgery
- 1 December 2018
- Published by Elsevier in Advances in Anesthesia
- Vol. 36 (1) , 99-123
Left Ventricular Assist Devices and Noncardiac Surgery
- Open Access
- 1 April 2018
- Published by Wolters Kluwer Health in Annals of Cardiac Anaesthesia
- Vol. 21 (2) , 215-217
Whole-lung Lavage in a Patient with Pulmonary Alveolar Proteinosis
Pulmonary alveolar proteinosis (PAP) is a rare syndrome in which phospholipoproteinaceous matter accumulates in the alveoli leading to compromised gas exchange. Whole-lung lavage is considered the gold standard for severe autoimmune PAP and offers favorable long-term outcomes. In this case report, we describe the perioperative management and procedural specifics of a patient undergoing WLL for PAP in which an anesthesiologist serves as the proceduralist and a separate anesthesiologist provides anesthesia care for the patient.
- 1 April 2018
- Published by Wolters Kluwer Health in Annals of Cardiac Anaesthesia
- Vol. 21 (2) , 215-217
Open AccessWhole-lung Lavage in a Patient with Pulmonary Alveolar Proteinosis
Pulmonary alveolar proteinosis (PAP) is a rare syndrome in which phospholipoproteinaceous matter accumulates in the alveoli leading to compromised gas exchange. Whole-lung lavage is considered the gold standard for severe autoimmune PAP and offers favorable long-term outcomes. In this case report, we describe the perioperative management and procedural specifics of a patient undergoing WLL for PAP in which an anesthesiologist serves as the proceduralist and a separate anesthesiologist provides anesthesia care for the patient.
- 1 April 2018
- Published by Wolters Kluwer Health in Journal of Ambulatory Care Management
- Vol. 41 (2) , 118-127
Same-Day Cancellation in Ambulatory Surgery
Although ambulatory surgery offers patients convenience and reduced costs, same-day cancellation of ambulatory surgery negatively affects patient experiences and operational efficiency. We conducted a retrospective analysis to determine the frequency and reasons for same-day cancellations in an outpatient surgery center at a large academic tertiary referral center. Of 41 389 ambulatory surgical procedures performed, same-day cancellations occurred at a rate of 0.5% and were usually unforeseeable in nature. Focusing on foreseeable cancellations offers opportunities for enhanced patient satisfaction, improved quality of care, and systems-based practice improvements to mitigate cancellations related to areas such as scheduling or patient noncompliance.
- 1 April 2018
- Published by Wolters Kluwer Health in Journal of Ambulatory Care Management
- Vol. 41 (2) , 118-127
Same-Day Cancellation in Ambulatory Surgery
Although ambulatory surgery offers patients convenience and reduced costs, same-day cancellation of ambulatory surgery negatively affects patient experiences and operational efficiency. We conducted a retrospective analysis to determine the frequency and reasons for same-day cancellations in an outpatient surgery center at a large academic tertiary referral center. Of 41 389 ambulatory surgical procedures performed, same-day cancellations occurred at a rate of 0.5% and were usually unforeseeable in nature. Focusing on foreseeable cancellations offers opportunities for enhanced patient satisfaction, improved quality of care, and systems-based practice improvements to mitigate cancellations related to areas such as scheduling or patient noncompliance.
- 15 March 2018
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 65 (9) , 1068-1069
Massive venous air embolism
- 15 March 2018
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 65 (9) , 1068-1069
Massive venous air embolism
- 1 February 2018
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 32 (1) , 151-157
Outcomes Following Three-Factor Inactive Prothrombin Complex Concentrate Versus Recombinant Activated Factor VII Administration During Cardiac Surgery
- 1 February 2018
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 32 (1) , 151-157
Outcomes Following Three-Factor Inactive Prothrombin Complex Concentrate Versus Recombinant Activated Factor VII Administration During Cardiac Surgery
- 1 November 2017
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 65 (5) , 588-589
Inferior vena cava tumour thrombus and renal cell carcinoma
- 1 November 2017
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 65 (5) , 588-589
Inferior vena cava tumour thrombus and renal cell carcinoma
- Open Access
- 1 November 2017
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 127 (5) , 902-903
Noninvasive Blood Pressure Determination in Left Ventricular Assist Device Patients
- 1 November 2017
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 127 (5) , 902-903
Open AccessNoninvasive Blood Pressure Determination in Left Ventricular Assist Device Patients
- 7 August 2017
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 64 (12) , 1267-1268
Bronchoesophageal fistula
- 7 August 2017
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 64 (12) , 1267-1268
Bronchoesophageal fistula
- 1 December 2016
- Published by Wolters Kluwer Health in Transplantation
- Vol. 100 (12) , 2723-2728
The Safety of Neuromuscular Blockade Reversal in Patients With Cardiac Transplantation
Background Neuromuscular blockade (NMB) reversal with neostigmine and glycopyrrolate has been reported to cause cardiac arrest in patients with a history of cardiac transplantation. The purpose of this study was to examine the safety of NMB reversal with acetylcholinesterase inhibitors and muscarinic anticholinergics in these patients. Methods We queried the medical records of a large tertiary referral center for patients with a history of prior heart transplantation who underwent anesthesia including receipt of NMB reversal. Patient records were reviewed to investigate maximal decrease in heart rate (HR) after NMB reversal and incidence of death and cardiac arrest. Results Seventy-seven heart transplant patients underwent 118 subsequent anesthetics during which they received neostigmine and glycopyrrolate for NMB reversal. No patients had active pacemakers at the time of their anesthetics. Mean time from heart transplantation to NMB reversal was 2.9 ± 3.2 (median, 1.9; range, 0.01– 12.5) years. After NMB reversal, no patients received atropine or epinephrine, suffered cardiac arrest, or died within 30 days. Mean HR decrease, defined as the difference between the HR immediately before NMB reversal and the lowest HR within 5 minutes thereafter, after NMB reversal was 0.5 ± 3.2 with median 0 (range, −8 to 17) beats per minute. Mean HR decrease was not associated with transplantation type (biatrial versus bicaval, P = 0.2029) or with increasing duration of time from cardiac transplantation (P = 0.0874). Conclusions Although rare cases of cardiac arrest after NMB reversal have been reported, our experience would support the safety of neostigmine and glycopyrrolate in cardiac transplantation patients.
- 1 December 2016
- Published by Wolters Kluwer Health in Transplantation
- Vol. 100 (12) , 2723-2728
The Safety of Neuromuscular Blockade Reversal in Patients With Cardiac Transplantation
Background Neuromuscular blockade (NMB) reversal with neostigmine and glycopyrrolate has been reported to cause cardiac arrest in patients with a history of cardiac transplantation. The purpose of this study was to examine the safety of NMB reversal with acetylcholinesterase inhibitors and muscarinic anticholinergics in these patients. Methods We queried the medical records of a large tertiary referral center for patients with a history of prior heart transplantation who underwent anesthesia including receipt of NMB reversal. Patient records were reviewed to investigate maximal decrease in heart rate (HR) after NMB reversal and incidence of death and cardiac arrest. Results Seventy-seven heart transplant patients underwent 118 subsequent anesthetics during which they received neostigmine and glycopyrrolate for NMB reversal. No patients had active pacemakers at the time of their anesthetics. Mean time from heart transplantation to NMB reversal was 2.9 ± 3.2 (median, 1.9; range, 0.01– 12.5) years. After NMB reversal, no patients received atropine or epinephrine, suffered cardiac arrest, or died within 30 days. Mean HR decrease, defined as the difference between the HR immediately before NMB reversal and the lowest HR within 5 minutes thereafter, after NMB reversal was 0.5 ± 3.2 with median 0 (range, −8 to 17) beats per minute. Mean HR decrease was not associated with transplantation type (biatrial versus bicaval, P = 0.2029) or with increasing duration of time from cardiac transplantation (P = 0.0874). Conclusions Although rare cases of cardiac arrest after NMB reversal have been reported, our experience would support the safety of neostigmine and glycopyrrolate in cardiac transplantation patients.